FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending February, 2009
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

Notificati
on of Transactions of Directors and
 Persons Discharging Managerial Responsibility

I give below details of changes in the interests of
:



No
.
 of Ordinary 
s
hares sold to meet tax liabilities following the vesting of a PSP award 
Dr M 
M 
Slaoui*
6,188
Mr S M Bicknell
1,293
Mr E J Gray 
2,738
Mr D Learmouth
1,293
Ms C Thomas
2,060
Mr D 
S 
Redfern
2,738


    * Denotes an Executive Director



No
.
 of 
ADSs
 
withheld 
to meet tax liabilities following the vesting of a PSP award
Mr W C Louv
990


    * Denotes an Executive Director

The Company, Directors, Persons Discharging Managerial Responsibility were advised of these transactions on 
20 February 2009
.

This notification relates to a transaction notified in accordance with
 
Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Deputy 
Company Secretary

20 February 2009
 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: February 20,  2009

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc